Alnylam Pharmace. buy StockNews.com
Start price
13.04.24
/
50%
€140.85
Target price
13.04.25
-
Performance (%)
45.76%
End price
14.04.25
€205.30
Summary
This prediction ended on 14.04.25 with a price of €205.30. The BUY prediction by StockNews_com for Alnylam Pharmace. saw massive gains of 45.76%. StockNews_com has a follow-up prediction for Alnylam Pharmace. where he still thinks Alnylam Pharmace. is a Buy. StockNews_com has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Alnylam Pharmace. | -2.307% | -2.307% | 48.466% |
| iShares Core DAX® | 0.323% | 2.208% | 21.610% |
| iShares Nasdaq 100 | 0.145% | -0.987% | 5.603% |
| iShares Nikkei 225® | 0.091% | -1.421% | 12.897% |
| iShares S&P 500 | 0.371% | -0.469% | 3.470% |
Comments by StockNews_com for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Ratings data for ALNY provided by MarketBeat
In the thread Trading Alnylam Pharmace.
Die von StockNews_com gewählte maximale Laufzeit wurde überschritten